ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
33.00
+0.70 (2.17%)
After Hours: 32.96 -0.04 (-0.12%)
May 2, 6:15PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.58 - 34.25
52 week 16.64 - 51.99
Open 34.16
Vol / Avg. 8.11M/4.11M
Mkt cap 3.71B
P/E     -
Div/yield     -
EPS -1.63
Shares 113.11M
Beta 3.72
Inst. own 91%
Jun 14, 2016
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
May 5, 2016
Q1 2016 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 2, 2016
ACADIA Pharmaceuticals Inc to discuss the FDA approval of NUPLAZID
Apr 12, 2016
ACADIA Pharmaceuticals Inc at Needham Healthcare Conference - Webcast
Mar 8, 2016
ACADIA Pharmaceuticals Inc at Cowen Health Care Conference - Webcast
Feb 29, 2016
Q4 2015 ACADIA Pharmaceuticals Inc Earnings Release
Feb 29, 2016
Q4 2015 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
Feb 10, 2016
ACADIA Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -269317.70% -269578.70%
Operating margin -268029.40% -269855.80%
EBITD margin - -268795.10%
Return on average assets -78.61% -60.09%
Return on average equity -85.99% -64.58%
Employees 160 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist (SSIA), targeting 5-HT2A receptors. The Company's Pimavanserin is a chemical entity, which has completed Phase III development, and is indicated for the treatment of Parkinson's disease psychosis. NUPLAZID (pimavanserin) is a selective serotonin inverse agonist preferentially targeting the 5-HT2A receptor, a key serotonin receptor that plays a role in psychosis. Through this mechanism, NUPLAZID has demonstrated efficacy in Parkinson's disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Stephen R. Davis President, Chief Executive Officer, Chief Financial Officer, Director
Age: 54
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Srdjan Stankovic M.D. Executive Vice President, Head - Research and Development
Age: 58
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 50
Bio & Compensation  - Reuters
James M. Daly Director
Bio & Compensation  - Reuters
Edmund P. Harrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 57
Bio & Compensation  - Reuters